Lab Reference Library / Mycotoxin Panel (Urinary) Detox, Mold & CIRS

Mycotoxin Panel (Urinary)

Mycotoxins · Urinary Mycotoxin Panel · Mold Toxin Screen

Reference range, optimal functional medicine levels, and why urinary mycotoxins confirm biotoxin absorption and systemic distribution in CIRS, how to distinguish building-source trichothecene and ochratoxin exposure from dietary aflatoxin and OTA from coffee and wine, and why cholestyramine binder therapy interrupts the enterohepatic mycotoxin recirculation driving C4a elevation.

CIRS Biotoxin MarkerEnvironmental Mold

TrichothecenesAny detection urgent

Ochratoxin ABelow 1 ppb optimal

AflatoxinsBelow detection

Unitsppb / ng/g Cr

← Back to Lab Reference Library

Category: Detox, Mold & CIRS | Also known as: Mold Toxin Panel, CIRS Urine Mycotoxins, Urinary Ochratoxin Trichothecene Aflatoxin

1. What This Test Measures

The mycotoxin panel measures urinary concentrations of secondary metabolites produced by toxigenic molds that colonize water-damaged buildings, improperly stored food, and agricultural commodities. Mycotoxins are small, lipophilic molecules (molecular weight 200 to 500 daltons) produced when specific mold species are under environmental stress, and they represent the mold's primary chemical defense and competitive mechanism. Unlike mold spores themselves, mycotoxins penetrate deep into lung tissue and across mucosal barriers, are absorbed into systemic circulation, and undergo biotransformation in the liver before partial renal excretion. Urine mycotoxin testing captures this excreted fraction, providing direct evidence of mycotoxin absorption and systemic distribution rather than simply environmental mold presence.

The clinically most important urinary mycotoxins fall into several structural classes. Trichothecenes are produced primarily by Stachybotrys chartarum (black mold) and Fusarium species; they include satratoxins, roridin E, verrucarin A, and T-2 toxin, and are among the most potent inhibitors of protein synthesis in eukaryotic cells, capable of inducing profound immune suppression, mucosal hemorrhage, and neurological damage at very low doses; trichothecene detection is the most alarming finding in a mycotoxin panel and warrants urgent environmental investigation and remediation. Ochratoxin A is produced by Aspergillus ochraceus, Aspergillus carbonarius, Penicillium verrucosum, and related species; it is both nephrotoxic (accumulating in renal proximal tubular cells) and immunosuppressive; has a long elimination half-life of approximately 35 days; and is the most commonly detected urinary mycotoxin in clinical panels from both building exposure and contaminated food (coffee, wine, dried fruits, cereals). Aflatoxins (B1, B2, G1, G2, and the liver metabolite M1) are produced by Aspergillus flavus and Aspergillus parasiticus; aflatoxin B1 is the most potent natural carcinogen known, classified as IARC Group 1 (definite human carcinogen); primary exposure route is food (corn, peanuts, tree nuts, spices) rather than building air, making its detection more likely to reflect dietary contamination than water-damaged building exposure. Gliotoxin is produced by Aspergillus fumigatus and other Aspergillus species; it is a potent immunosuppressant that inhibits NF-kB and promotes apoptosis in immune cells; detection indicates active Aspergillus exposure from either a water-damaged building or, importantly, invasive aspergillosis in immunocompromised patients.

Urinary mycotoxin panels are available through specialty laboratories (RealTime Laboratories, GPL/Great Plains Laboratory, Vibrant America) and use liquid chromatography-mass spectrometry (LC-MS/MS) for detection and quantification. This technology provides high sensitivity and specificity for individual mycotoxin identification, distinguishing clinical panels from older immunoassay-based tests with poorer analytic performance. The clinical interpretation challenge is that population reference ranges are based on small datasets, and the relationship between urinary mycotoxin levels and clinical illness severity is not established with the precision available for some other biomarkers. Urinary mycotoxins confirm exposure and absorption; the clinical diagnosis of CIRS from mycotoxin exposure requires the full Shoemaker panel (C4a, MSH, TGF-beta1, MMP-9, VEGF, VIP) alongside the exposure history and urinary confirmation.

2. Mycotoxin Classes and Reference Ranges

Mycotoxin	Primary Producer	Clinical Target	Detection Threshold
Ochratoxin A (OTA)	Aspergillus, Penicillium	Kidney, immune system	Below detection optimal; 1 ppb action threshold
Satratoxins / Trichothecenes	Stachybotrys, Fusarium	Protein synthesis, mucosa, CNS	Any detection is clinically significant
Aflatoxins (B1, B2, G1, G2)	Aspergillus flavus, parasiticus	Liver (carcinogen), immune	Below detection optimal; any detection warrants investigation
Gliotoxin	Aspergillus fumigatus	Immune suppression	Below detection optimal; evaluate for invasive aspergillosis
Mycophenolic acid	Penicillium species	Immune, renal	Below detection optimal
Zearalenone (ZEA)	Fusarium species	Endocrine disruption (estrogenic)	Below detection optimal; primarily grain/food source

No established clinical reference ranges exist with the precision available for many other laboratory tests. Results are reported as detected or not detected at the laboratory's lower limit of quantification, with detected values reported in parts per billion (ppb) or nanograms per gram creatinine for creatinine-adjusted specimens. Any detected trichothecene warrants urgent evaluation. Ochratoxin A is the most commonly detected urinary mycotoxin in non-occupationally exposed individuals. Results must always be interpreted alongside environmental testing (ERMI, HERTSMI-2) and the full CIRS immune panel.

3. CIRS vs Dietary Mycotoxin Exposure: A Critical Distinction

Building-Source Mycotoxin Exposure

Primary mycotoxins: trichothecenes (Stachybotrys), gliotoxin (Aspergillus fumigatus), ochratoxin A (Aspergillus, Penicillium), mycophenolic acid; the specific pattern of detected mycotoxins can be cross-referenced against the mold species identified on building ERMI testing to confirm concordance between the environmental and urinary findings
Clinical presentation: building-source CIRS produces the full Shoemaker immune dysregulation panel: elevated C4a, low MSH, elevated TGF-beta1, elevated MMP-9, low VEGF, low VIP; neurological symptoms (brain fog, cognitive impairment, sleep disruption, pain amplification) predominate alongside fatigue, and symptoms worsen in the implicated building and improve when the patient leaves for extended periods
Environmental confirmation: ERMI score above 2 in the home or workplace; HERTSMI-2 score above 11; visual evidence of water damage, musty odor, past flooding, or persistent humidity above 60%; VCS (Visual Contrast Sensitivity) test positive at baseline with improvement during periods of confirmed exposure removal
HLA-DR susceptibility: genetically susceptible patients (approximately 24% of the population) cannot clear building-derived biotoxins through normal adaptive immune antibody responses, explaining why cohabitants in the same building differ dramatically in illness severity; HLA-DR typing identifies susceptibility and guides treatment intensity planning

Dietary Mycotoxin Exposure

Primary mycotoxins: ochratoxin A (coffee, wine, dried fruits, grape juice, cereals, processed meats), aflatoxins (peanuts, corn, tree nuts, spices including paprika and chili, figs), zearalenone (corn, wheat, barley, animal products from exposed livestock), deoxynivalenol or DON (wheat, oats, barley, corn); dietary mycotoxins are strictly regulated by FDA and EU maximum residue limits for food safety, but poorly stored commodities and unregulated supplements can contain significant levels
Clinical significance: dietary mycotoxin exposure rarely triggers the full CIRS immune dysregulation cascade in HLA-DR-normal individuals, as these mycotoxins are typically cleared through normal hepatic biotransformation; however, in HLA-DR-susceptible individuals, dietary mycotoxins may contribute to the biotoxin body burden that perpetuates CIRS alongside building exposure; high-ochratoxin-A food consumption may also directly cause nephrotoxicity and immunosuppression independently of CIRS mechanism
Distinguishing feature: ochratoxin A detected in urine without CIRS-consistent ERMI findings or CIRS immune panel abnormalities should prompt dietary investigation rather than building remediation; detailed dietary history focusing on coffee consumption (single largest OTA source in Western diets), wine, dried fruits, and whole grain cereals will identify the dietary source in most cases
Aflatoxin detection: aflatoxin in urine almost always reflects dietary exposure (peanuts, corn, tree nuts, spices) rather than building air exposure; Aspergillus flavus and parasiticus rarely colonize temperate climate building environments; aflatoxin detection warrants food source investigation and repeat testing after dietary modification to confirm reduction

4. Trichothecenes: The Most Concerning Mycotoxin Finding

Detection of trichothecenes (satratoxin G, satratoxin H, roridin A, roridin E, verrucarin A, T-2 toxin, HT-2 toxin) in urine is the single most alarming mycotoxin panel finding and demands immediate, aggressive environmental investigation and patient removal from the exposure source.

Trichothecenes are the primary mycotoxin output of Stachybotrys chartarum (black mold) and several Fusarium species, and are the most potent known inhibitors of eukaryotic protein synthesis. They act by binding the ribosomal peptidyl transferase active site, halting amino acid chain elongation and triggering ribosome arrest. At the cellular level, this produces rapid apoptosis in actively dividing cells (particularly mucosal epithelium, hematopoietic precursors, and immune cells), explaining the mucosal hemorrhage, immune suppression, and bone marrow toxicity associated with high-dose trichothecene exposure. The weaponized trichothecene T-2 toxin was investigated as a biological warfare agent, providing a measure of the toxicity potential at high doses. At the much lower concentrations encountered in water-damaged buildings, trichothecene exposure produces the clinical CIRS picture with particular prominence of fatigue, cognitive impairment, immune suppression, recurrent infections, and in severe cases, bleeding from mucosal surfaces.

Stachybotrys chartarum requires sustained cellulose substrate saturation (not merely humidity) for colonization and trichothecene production, so its presence indicates prolonged and severe water intrusion rather than minor humidity elevation. It is characteristically found on drywall paper, ceiling tiles, cardboard, and wood that has been continuously wet for weeks to months. ERMI testing identifying Stachybotrys alongside urinary trichothecene detection provides compelling environmental-biological concordance for building-source CIRS. The standard approach upon trichothecene detection is: immediate removal of the patient from all suspect environments, urgent ERMI or IEP inspection of home and workplace, and initiation of the Shoemaker CIRS protocol with binder therapy while environmental investigation is ongoing.

5. Ochratoxin A: The Most Common Finding and Its Sources

Coffee as the dominant dietary OTA source: coffee beans colonized by Aspergillus and Penicillium species during improper post-harvest drying or storage accumulate significant ochratoxin A; OTA survives roasting and coffee preparation (only 50 to 80% is destroyed at roasting temperatures); European population studies identify coffee as the single largest OTA dietary exposure source for adult consumers; patients with high urinary OTA who are heavy coffee consumers should trial a 30-day coffee elimination to determine whether coffee is the primary contributor before attributing elevation to building exposure
Wine, particularly red wine: OTA is produced by Aspergillus carbonarius on grape skins during vineyard growth and post-harvest; it survives wine production and is present at measurable levels in conventional wines; organic wines produced without fungicide use may paradoxically have higher OTA from greater Aspergillus growth; OTA in wine is regulated by EU maximum limits but not by the US FDA
Dried fruits: raisins, dried figs, prunes, and apricots can accumulate OTA during drying and storage if moisture control is inadequate; OTA contamination of dried fruits is regulated internationally but remains a source of variable exposure
Grain-based foods: whole grain cereals, bread, and processed grain products can contain OTA from field contamination with Penicillium verrucosum in temperate climates; the UK Food Standards Agency identifies cereal products as the second most significant OTA exposure source after coffee in European populations
OTA renal toxicity mechanism: OTA accumulates in renal proximal tubular cells through organic anion transporters (OAT1, OAT3), where it inhibits mitochondrial respiration, induces oxidative DNA damage, promotes lipid peroxidation, and activates apoptotic pathways; chronic low-level OTA exposure produces progressive tubular dysfunction before clinical creatinine elevation occurs; urinary beta-2 microglobulin and N-acetyl glucosaminidase are early markers of OTA-related tubular injury that precede GFR decline
OTA immunosuppression: OTA inhibits phagocytic function of macrophages and dendritic cells, reduces lymphocyte proliferation, and suppresses antibody production; chronic dietary OTA exposure may contribute to the immune impairment and recurrent infection susceptibility seen in some CIRS patients even when building mycotoxin exposure is the primary driver

6. Supporting Mycotoxin Elimination

Environmental and Dietary Source Control

Confirmed building exposure elimination: ERMI dust sampling of home and workplace; IEP (independent environmental professional) inspection; professional mold remediation following IICRC S520 guidelines; post-remediation clearance testing before re-entry; while remediation is ongoing, patient must be housed in confirmed safe environment
Dietary source reduction for OTA: eliminate or significantly reduce coffee (trial complete elimination for 30 days and retest), reduce wine consumption (one glass daily maximum during mycotoxin reduction protocol), eliminate dried fruits high in OTA, and choose organic certified grain products where possible
Aflatoxin dietary reduction: choose organic peanut butter and tree nuts (aflatoxin contamination is lower in organic and freshly ground products); inspect stored grains and nuts for visible mold growth and discard any questionable product; avoid bulk bin nuts, grains, and spices that may have variable storage quality
HEPA filtration in living space: high-efficiency particulate air filtration captures airborne mold spores and mycotoxin-bearing particles; MERV-13 or true HEPA units in all living areas and bedroom during building remediation and recovery; reduces ongoing inhalation exposure while full remediation is completed
Personal protective equipment during remediation: if the patient must temporarily re-enter the contaminated building, N95 or P100 respirator, gloves, and protective clothing reduce inhalation exposure; shower and change clothes immediately after exposure

Prescription Binder Protocol

Cholestyramine (CSM) 4g four times daily: the primary prescription binder for building-source mycotoxin CIRS; binds fat-soluble mycotoxins (including trichothecenes, ochratoxin A, zearalenone) in the intestinal lumen before enterohepatic reabsorption; must be taken 30 to 60 minutes before meals and separated from all medications by at least 4 hours; continue for 30 days with repeat CIRS panel monitoring
Welchol (colesevelam) 625mg three tablets twice daily: alternative binder for patients who cannot tolerate cholestyramine due to GI side effects; bile acid sequestrant mechanism similar to CSM; better tolerated, slightly less potent for mycotoxin binding; appropriate for patients with constipation or significant bloating on cholestyramine
Activated charcoal (1 to 2g between meals): broad-spectrum mycotoxin adsorbent; binds aflatoxins, ochratoxin A, and zearalenone in the gut; useful as adjunctive support alongside prescription binders or as primary OTC binder for mild exposure reduction during dietary source elimination; must be separated from medications and supplements
GI Detox (bentonite clay and charcoal): OTC combination adsorbent; binds multiple mycotoxin classes including aflatoxins and OTA; lower binding capacity than prescription CSM but useful as part of a comprehensive mycotoxin reduction protocol

Nutritional Detoxification Support

Glutathione (liposomal 500mg daily or NAC 600mg twice daily): mycotoxins undergo glutathione conjugation as a primary phase II hepatic detoxification pathway; ochratoxin A glutathione conjugate is measurably excreted in urine; optimizing glutathione through NAC (cysteine precursor), glycine, and glutamate supports the rate-limiting step in mycotoxin conjugation and excretion
Milk thistle (silymarin standardized extract, 420mg daily): protects hepatocytes from mycotoxin-induced damage through antioxidant, anti-inflammatory, and protein synthetic effects; silymarin competitively inhibits OTA uptake at hepatocyte organic anion transporters; also promotes bile flow, enhancing biliary mycotoxin excretion; one of the most evidence-based hepatoprotective supplements for mycotoxin exposure
Vitamin C (2,000 to 4,000mg daily in divided doses): reduces mycotoxin-induced oxidative stress; aflatoxin-induced DNA damage is partially attenuated by vitamin C; general antioxidant support for phase I detoxification byproduct management
Alpha-lipoic acid (600mg daily): fat and water-soluble antioxidant that reduces mycotoxin-induced lipid peroxidation; recycles glutathione from its oxidized form back to the active reduced form; crosses cell membranes to provide intracellular antioxidant support in hepatocytes and renal tubular cells targeted by OTA
Probiotics (spore-forming strains): Bacillus coagulans and Saccharomyces boulardii have demonstrated OTA and aflatoxin binding in the intestinal lumen through cell wall beta-glucan interactions; reduce mycotoxin bioavailability from dietary sources while restoring microbial diversity disrupted by mycotoxin-induced gut dysbiosis
Sauna therapy (infrared or traditional): promotes mycotoxin excretion through sweat; evidence for urinary and sweat-based trichothecene elimination with regular sauna use; adjunctive to binder therapy rather than replacing it; 20 to 30 minutes at moderate temperature three to four times weekly; ensure electrolyte and fluid replacement

7. Related Lab Tests

C4aPrimary Immune Response Marker Confirming Biotoxin-Driven Complement Activation

→

MSHCentral CIRS Regulatory Depletion Marker; Always Measured Alongside Mycotoxin Panel

→

TGF-beta1Pro-Fibrotic CIRS Cascade Marker Driven by Mycotoxin Immune Activation

→

MMP-9Blood-Brain Barrier Disruption Marker Driven by Mold-Activated Macrophages

→

Heavy MetalsEnvironmental Co-exposure Assessment; Mycotoxins and Heavy Metals Frequently Co-occur

→

GlyphosateHerbicide Exposure Companion in Comprehensive Environmental Medicine Evaluation

→

8. Clinical Perspective

Clinical Perspective

The mycotoxin panel is the test that closes the loop between the environmental exposure and the immune response. When a patient presents with the full CIRS immune panel pattern and I see C4a of 29,000 and MSH of 16, I already know from the immune markers that there is a biotoxin driving this. The mycotoxin panel tells me which biotoxins are actually being absorbed into this patient's system and excreted in their urine, and that information changes the specificity of the environmental investigation and the binder protocol. Ochratoxin A detected at 4.2 ppb tells me that Aspergillus or Penicillium is the primary mold genus driving the exposure, and that directs the ERMI interpretation toward ochratoxin-producing species. Satratoxin detected at any level tells me Stachybotrys is present and this patient must leave their environment today, not after remediation is scheduled. The mycotoxin panel also helps me distinguish building-source CIRS from patients whose ochratoxin is being driven primarily by daily coffee consumption rather than a water-damaged building, which saves a family from an unnecessary and expensive remediation. The clinical nuance of that distinction matters enormously. Mycotoxin testing is most powerful when it is integrated with the full environmental and immune marker picture rather than interpreted as a standalone result, and that integrated interpretation is where the diagnosis becomes actionable.

Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma

9. Frequently Asked Questions

Is a positive urinary mycotoxin test diagnostic for CIRS?

Urinary mycotoxin detection confirms that mycotoxins have been absorbed and are being excreted but does not by itself diagnose CIRS. Many people have detectable dietary mycotoxins (particularly ochratoxin A from coffee) without developing CIRS, because the approximately 76% of the population without susceptible HLA-DR variants can clear biotoxins through normal adaptive immune antibody responses. A positive mycotoxin panel becomes diagnostically significant for CIRS when it is accompanied by the full immune panel pattern (elevated C4a, low MSH, elevated TGF-beta1, elevated MMP-9, low VEGF and VIP), a plausible water-damaged building exposure history, and clinical symptoms consistent with CIRS.

Why should I test for speciated arsenic separately from mycotoxins?

Urinary arsenic should be speciated (inorganic vs organic fractions) whenever arsenic is included in an environmental toxin panel. Seafood contains large amounts of non-toxic organic arsenobetaine that elevates total arsenic dramatically without clinical significance. Attributing a high total arsenic to mold exposure rather than seafood consumption would lead to unnecessary environmental investigation. Speciated testing identifies only the toxic inorganic arsenic fraction, allowing accurate clinical interpretation. This is a separate test from the mycotoxin panel but is commonly ordered alongside it in comprehensive environmental medicine evaluations.

Can urinary mycotoxins be elevated from diet alone without building exposure?

Yes. Ochratoxin A is commonly detected in people whose primary exposure is dietary (coffee, wine, dried fruits, cereals) rather than building-related. Aflatoxin detection almost always reflects dietary exposure from peanuts, corn, tree nuts, or contaminated spices rather than building air, because the aflatoxin-producing Aspergillus species prefer tropical climates and typically do not colonize temperate-climate buildings. Zearalenone and deoxynivalenol from contaminated grains are predominantly dietary in origin. Only trichothecenes from Stachybotrys and gliotoxin from Aspergillus fumigatus are primarily associated with building exposure rather than food.

How long does it take for urinary mycotoxins to clear with binder therapy?

Clearance rates vary by mycotoxin class and half-life. Ochratoxin A has a biological half-life of approximately 35 days, so urinary OTA levels fall slowly even with aggressive binder therapy and exposure elimination; complete clearance may require 90 to 180 days. Trichothecenes have shorter elimination half-lives but tissue redistribution can prolong detectable urinary excretion beyond the plasma half-life. Aflatoxin metabolites clear within days to weeks of dietary exposure cessation. Repeat mycotoxin panel testing at 60 to 90 days confirms treatment response; for OTA specifically, 90 to 120 days is a more informative retest interval.

What is the difference between a certified mold inspector and ERMI testing?

ERMI (Environmental Relative Moldiness Index) is a standardized DNA-based dust sampling test that quantifies specific mold species from settled dust, providing a calculated score based on the ratio of water-damage-indicator species to common outdoor species. It is objective, reproducible, and does not require interpretation by the sampler. An IEP (independent environmental professional) certified mold inspector performs visual inspection, moisture mapping, air sampling, and surface sampling, providing a broader assessment of building conditions but with results more dependent on inspector skill and judgment. ERMI is the primary tool recommended in the Shoemaker CIRS framework; IEP inspection adds important structural information about moisture sources and the extent of contamination that ERMI alone does not provide. Both are most informative together.

Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.

Urinary mycotoxin detection closes the loop between environmental exposure and immune response, identifying the specific biotoxin classes driving the CIRS panel abnormalities and directing targeted binder therapy and remediation.

Mycotoxin panel interpretation requires integration with the full CIRS immune panel and environmental testing. Schedule a consultation for a comprehensive biotoxin illness evaluation and structured treatment plan.

Schedule a Consultation

Medical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Lab interpretation should always be performed in clinical context by a qualified healthcare provider. Reference ranges and optimal targets may vary based on individual patient history, clinical presentation, and laboratory methodology. Schedule a consultation to discuss your specific results with Dr. Lamkin.